

**Table 2.** Symptoms of PHEOs/PGLs according to their neurosecretory products and in particular of Neuropeptide Y (NPY), which is a vasoactive peptide that may contribute to their clinical presentation. Patients with MEN2 or sporadic PHEOs show high levels of NPY compared to VHL-associated tumors (modified/adapted from<sup>3,19</sup>)

	<b>High NPY expression</b>		<b>Low NPY expression</b>
	<b>MEN2</b>	<b>Sporadic disease</b>	<b>VHL</b>
Hypertension (%)	42	90	19
Headache (%)	32	92	26
Diaphoresis (%)	32	70	23
Palpitations (%)	37	73	19
Anxiety (%)	21	60	16
Total symptoms (%)	53	90	32